Delayed Drug In New Zealand Markets

by Medindia Content Team on  June 26, 2006 at 12:06 PM Drug News   - G J E 4
Delayed Drug In New Zealand Markets
Diabetics in New Zealand are welcoming a Pharmac decision to fund long-acting insulin, that has been available abroad for years.

The government agency that purchases drugs announced yesterday that it would fund the insulin, glargine, from July 1. It is also known by its trade name, Lantus.

Wayne McNee, Pharmac chief executive, said the drug, which was priced at $5 million, reduces the risk of hypo glycaemia which could lead to muscle weakness, confusion and sweating, and in the worst cases, to coma.

Community liaison officer of Diabetes Society, Lynne Taylor, welcomed the decision, but said it had taken too long for Pharmac to come out with the drug, as the patient lobby has been demanding it for at least 18 months.

Complications of un-controlled diabetes include problems of the eye, kidney and heart.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All